Evidence map›Paper›PMID 33743082›Full record

SynthesisActa diabetologica2021

Continuous glucose monitoring in patients with type 2 diabetes on hemodialysis.

Maurizio Gallieni, Cristina De Salvo, Maria Elena Lunati, Antonio Rossi, Francesca D'Addio, Ida Pastore, Gianmarco Sabiu, Roberta Miglio, Gian Vincenzo Zuccotti, Paolo Fiorina

Open access · hybridAbstract readSystematic Review
In one paragraph

Synthesis in Acta diabetologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Diabetes and Glucose Management in People on Hemodialysis.Diabetes spectrum : a publication of the American Diabetes Association · 2025
    Article
  6. Article
  7. Observational
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Maurizio GallieniDepartment of Biomedical and Clinical Sciences "Luigi Sacco", Università Di Milano, Milano, Italy. maurizio.gallieni@unimi.it.ORCID http://orcid.org/0000-0002-2011-2160
Cristina De SalvoNephrology and Dialysis Unit, ASST Fatebenefratelli Sacco, Milano, Italy.
Maria Elena LunatiDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy.
Antonio RossiDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy.
Francesca D'AddioInternational Center for T1D, Pediatric Clinical Research Center Romeo Ed Enrica Invernizzi, Department of Biomedical and Clinical Sciences "L. Sacco", Università Di Milano, Milan, Italy.
Ida PastoreDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy.
Gianmarco SabiuNephrology and Dialysis Unit, ASST Fatebenefratelli Sacco, Milano, Italy.
Roberta MiglioNephrology and Dialysis Unit, ASST Fatebenefratelli Sacco, Milano, Italy.
Gian Vincenzo ZuccottiPediatric Clinical Research Center Romeo Ed Enrica Invernizzi, Department of Biomedical and Clinical Sciences "L. Sacco", Università Di Milano and Pediatric Department, Buzzi Children's Hospital, Milan, Italy.
Paolo FiorinaDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy.ORCID http://orcid.org/0000-0002-1093-7724
ASST Fatebenefratelli Sacco · ITBoston Children's Hospital · USLuigi Sacco Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic kidney disease is the leading cause of end-stage kidney disease in high-income countries. The strict control of glycemic oscillations is the principal therapeutic target, but this could be hard to achieve in uremic patients due to their unpredictable insulin sensitivity. Currently, the evaluation of the glycemic profile relies on serum markers (glycated hemoglobin HbA1c, glycated albumin, and fructosamine), capillary glucose blood control (self-monitoring of blood glucose), and interstitial glucose control (continue glucose monitoring). We conducted a systematic review of published articles on continue glucose monitoring in hemodialysis patients with type 2 diabetes, which included 12 major articles. Four studies found significant fluctuations in glucose levels during hemodialysis sessions. All studies reported a higher mean amplitude of glucose variations on the hemodialysis day. Three studies agreed that continue glucose monitoring is better than glycated hemoglobin in detecting these abnormalities. Moreover, continue glucose monitoring was more accurate and perceived as easier to use by patients and their caregivers. In patients with type 2 diabetes on hemodialysis, glucose levels show different variation patterns than the patients on hemodialysis without diabetes. Considering manageability, accuracy, and cost-effectiveness, continue glucose monitoring could be the ideal diagnostic tool for the patient with diabetes on hemodialysis.

Indexed as

Renal DialysisAgedBiomarkersBlood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 2Diabetic NephropathiesFemaleFructosamineGlycated HemoglobinGlycated Serum AlbuminGlycation End Products, AdvancedGlycemic ControlHumansKidney Failure, ChronicMaleBiomarkersBlood GlucoseFructosamineGlycated HemoglobinGlycated Serum AlbuminGlycation End Products, AdvancedSerum AlbuminChronic kidney diseaseContinuous glucose monitoringDiabetes mellitusHemodialysis

Identifiers

PMID33743082
PMCPMC8272699
OpenAlexW3138501292

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.